Florida Woman Sues Novo, Alleges Ozempic Caused Blindness
Florida Woman Sues Novo Nordisk, Alleges Ozempic Caused Permanent Blindness Through Rare Eye Condition NAION- A New Filing in the Growing GLP-1 Vision Loss Litigation On July 28, 2026, a Florida woman filed a product liability lawsuit complaint (pdf) against Novo Nordisk Inc. and Novo Nordisk A/S in the U.S. District Court for the Eastern […]
Novo Nordisk Shareholder Lawsuit Over CagriSema
A federal judge has allowed a securities fraud lawsuit against Novo Nordisk to move forward, in a ruling that offers a useful window into how courts evaluate claims that a pharmaceutical company misled its own investors about clinical trial design and results. The case centers on CagriSema, Novo’s experimental next-generation obesity drug, and specifically on […]
Australia’s drug regulator issues mental health warning for weight-loss drugs including Ozempic
TGA Also Warns That Mounjaro May Reduce Effectiveness of Oral Contraceptives Last updated: July 2026 | Regulator: Therapeutic Goods Administration (TGA), Australia | Read time: ~10 min If you are experiencing thoughts of suicide or self-harm, please contact the 988 Suicide and Crisis Lifeline by calling or texting 988. You can also reach the Crisis […]
Novo Nordisk vs. Eli Lilly: Inside the GLP-1 False Advertising Lawsuit
Novo Nordisk vs. Eli Lilly: Inside the GLP-1 False Advertising Lawsuit The rivalry between the world’s two dominant weight-loss and diabetes drug makers has escalated into a full-blown federal lawsuit. On July 21, 2026, Novo Nordisk Inc. filed suit against Eli Lilly and Company and its subsidiary Lilly USA, LLC in the U.S. District Court […]
Are GLP-1 Drugs Athletic Performance Enhancers?
Serena Williams, WADA Monitoring, and the Questions Sports Regulators Are Starting to Ask Last updated: July 2026 | Covers: Ozempic, Wegovy, Mounjaro, Zepbound — GLP-1 drugs in sport | Read time: ~12 min GLP-1 receptor agonists — Ozempic, Wegovy, Mounjaro, Zepbound, and their counterparts — are usually discussed in the context of managing Type 2 […]
FDA Raises Safety Concerns RE: Unapproved GLP-1 for Weight Loss
Counterfeit Products, Dosing Errors, Illegal Online Sales, and Quality Failures in the Compounded GLP-1 Market Source: FDA Drug Safety Communications | Data as of July 2nd, 2026 | Read time: ~9 min The U.S. Food and Drug Administration has issued a comprehensive warning about the risks posed by unapproved, compounded, and counterfeit versions of GLP-1 […]
Do GLP-1s Increase Testosterone Levels?
The latest generation of weight-loss medications may offer an unexpected benefit beyond helping people shed pounds: improved male fertility. According to a systematic review presented at the Endocrine Society’s annual meeting in Chicago, GLP-1 receptor agonists may increase testosterone levels and improve sperm quality in men with obesity. Researchers caution that the evidence remains preliminary. […]
GLP-1 Lawsuits Mount as Patients Report Severe Injuries
Gastroparesis, Vision Loss, Bowel Obstruction, and Other Alleged Complications Last updated: June 2026 | Covers: Ozempic, Wegovy, Mounjaro, Zepbound, The Ozempic Pill (aka Rybelsus), Trulicity, Saxenda, Victoza | Read time: ~13 min The number of lawsuits involving GLP-1 weight-loss and diabetes medications continues to climb across the United States, and the scope of the alleged […]
Mayim Bialik’s Experience With a GLP-1 Drug Highlights Ongoing Questions About Side Effects
Actress Reports Weeks of Gastrointestinal Symptoms After a Single Injection Last updated: June 2026 | Covers: GLP-1 side effects, gastrointestinal complications | Read time: ~8 min The public conversation around GLP-1 medications — Ozempic, Wegovy, Mounjaro, Zepbound, and their counterparts — has been shaped largely by before-and-after weight loss accounts and by the clinical trial […]
FDA Warns Novo Nordisk Over Alleged Failures to Report Ozempic and Wegovy Side Effects
Agency Cites Serious Violations of Federal Adverse Event Reporting Requirements for Semaglutide Last updated: May 2026 | Warning letter date: March 5, 2026 | Drug: Ozempic / Wegovy (semaglutide) | Read time: ~9 min In March 2026, the U.S. Food and Drug Administration issued a formal warning letter to Novo Nordisk — the manufacturer of […]